Pregnancy: Sodium Valproate

(asked on 23rd April 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of whether the NICE guideline for epilepsy on sodium valproate as first-line treatment for children, young people and adults with newly diagnosed juvenile myoclonic epilepsy is compatible with the Medicines and Healthcare Products Regulatory Agency pregnancy prevention programme.


Answered by
Seema Kennedy Portrait
Seema Kennedy
This question was answered on 1st May 2019

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the wording of its guideline recommendations. NICE has advised that it will ensure that its recommendations on the use of sodium valproate are consistent with the regulatory position, as set out by the Medicines and Healthcare products Regulatory Agency. The two organisations are working closely together to ensure that this is the case.

Reticulating Splines